Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (281-290 of 315) with videos related to

Pageof 32
Sort By:
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 8, 2022
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory DiseasesG Walter Canonica, Arnaud Bourdin, Anju T Peters, et al.
JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
JAMA Dermatology|April 12, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical TrialsAmy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, et al.
Lancet (London, England)|February 23, 2020
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trialJoanne R Chalmers, Rachel H Haines, Lucy E Bradshaw, et al.
Pageof 32

Showing results (281-290 of 315) with videos related to

Sort By:
Pageof 32
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology|January 22, 2021
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or AsthmaAshish Bansal, Eric L Simpson, Amy S Paller, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
Lancet (London, England)|October 12, 2015
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Eric L Simpson, Lisa A Beck, et al.
Lancet (London, England)|May 23, 2021
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 8, 2022
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory DiseasesG Walter Canonica, Arnaud Bourdin, Anju T Peters, et al.
JAMA Dermatology|October 23, 2024
Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 WeeksAmy S Paller, Pedro Mendes-Bastos, Elaine Siegfried, et al.
JAMA Dermatology|April 12, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical TrialsAmy S Paller, Barry Ladizinski, Pedro Mendes-Bastos, et al.
Lancet (London, England)|February 23, 2020
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trialJoanne R Chalmers, Rachel H Haines, Lucy E Bradshaw, et al.
Pageof 32